Form 4: Adaptive Biotechnologies COO Acquires 81,250 Shares

Adaptive Biotechnologies' President and COO, Julie Rubinstein, acquired 81,250 shares of common stock on March 4, 2026.

Summary

• Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp (ADPT), acquired 81,250 shares of common stock.
• The transaction occurred on March 4, 2026.
• The acquisition price was $0 per share, indicating a grant or award.
• Following this transaction, Julie Rubinstein beneficially owns a total of 656,485 shares of common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as an insider increasing their stake, even through a grant, demonstrates confidence in the company's future.

Positives

• A high-ranking insider, the President and COO, increased her stake in the company by acquiring 81,250 shares.
• The acquisition, likely a grant at $0, aligns management's financial interests with those of shareholders, signaling confidence in the company's future.

Industry Context

StockSavvy.ai notes that insider acquisitions, especially by high-ranking executives like a President and COO, can signal management's confidence in the company's future prospects within the biotechnology sector. This aligns the executive's personal financial interests with the long-term performance of Adaptive Biotechnologies.

Comparison to Industry Standards

• Insider buying activity is generally viewed positively across all industries, as it indicates management's belief in the company's value.
• While specific comparable companies or projects are not detailed in this Form 4, similar insider acquisitions at biotech firms like Moderna or BioNTech during periods of strategic growth or positive clinical trial results are often interpreted as strong bullish signals.

Stakeholder Impact

• Shareholders: Potentially positive signal due to increased insider confidence in the company's prospects.
• Employees: No direct impact mentioned.
• Customers, Suppliers, Creditors: No direct impact mentioned.

Key Dates

Recommendation

The acquisition of shares by a key executive is a positive indicator of internal confidence. However, as this appears to be a grant rather than an open market purchase, and without additional financial or strategic context, a 'hold' recommendation is prudent, awaiting further company developments or broader market analysis.

Keywords

Adaptive Biotechnologies, ADPT, Julie Rubinstein, Insider Transaction, Form 4, Stock Acquisition, Common Stock, Biotechnology, Officer Compensation